Summary
ARS Pharmaceuticals has a recently launched needle-free epinephrine product for allergic reactions, neffy. See why I rate SPRY stock a buy.
Source: Seeking Alpha
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
